Does Higher Diastolic Augmentation Predict Clinical Benefit from Enhanced External Counterpulsation?

来源 :中国老年学会体外反搏与心血管康复论坛暨第二届国际体外反搏学术交流会 | 被引量 : 0次 | 上传用户:szjtznh
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
其他文献
会议
会议
Patients with coronary artery disease have a variety of treatment options available to them.These include medications to control anginal episodes and,when appropriate,revascularization interventions i
会议
EECP is a non-invasive outpatient treatment for cardiovascular disease refractory to medical and/or surgical therapy.It has been cleared by the Food and Drug Administration for the treatment of a vari
会议
会议
The International Enhanced External Counterpulsation (EECP) Patient Registry tracks acute and long-term outcome for consecutive patients treated for chronic angina.Although EECP has previously been sh
会议
Among 2,486 patients enrolled in the International EECP Patient Registry (IEPR) who underwent EECP therapy for symptomatic coronary artery disease,the median diastolic augmentation (DA) ratio increase
会议
Enhanced external counterpulsation (EECP) has recently emerged as a treatment option for angina in selected patients suitable for revascularization with percutaneous coronary intervention (PCI).We com
会议
Enhanced external counterpulsation (EECP) is used to noninvasively treat refractory angina patients,including those with a history of heart failure.The International EECP Patient Registry was used to
会议
Clinical restenosis following coronary artery angioplasty (PTCA) occurs in up to 30% of the patients within 6 months of treatment.Endothelial dysfunction in diseased and/or mechanically injured arteri
会议